News
Johnson & Johnson shrugs off tariff impact and forecasts sales boost
Johnson & Johnson has shrugged off the impact of tariffs as the US-based healthcare group raised its earnings and sales guidance for 2025. J&J, which warned of $400mn in duty costs following President Donald Trump’s “liberation day” tariffs announcement in April,
4hon MSN
The drug and medical device maker Johnson & Johnson kicked off the healthcare earnings season with a better-than-anticipated ...
Johnson & Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year ...
Johnson & Johnson raised its full-year sales forecast on Wednesday after beating estimates for second-quarter profit on ...
The Motley Fool. DATE Wednesday, July 16, 2025 at 8:30 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer — ...
C.J. Gardner-Johnson said he "retracts" the comments he made about the Philadelphia Eagles after he was traded to the Houston ...
Johnson shared yet another personal insight that nobody asked for: His jizz has substantially more microplastics in it than ...
The third-term Democrat from Dallas faces long odds in a state that has only elected Republicans to statewide office for ...
Stay updated on Johnson & Johnson's Q2 earnings as it faces tariff threats, MedTech challenges, and legal risks.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback